CLINICAL TRIAL: IMPAACT 1071

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 在第I阶段，评价vicriviroc联合优化背景治疗（包括利托那韦增强蛋白酶抑制剂方案）在HIV感染、有治疗经验的儿童和青少年中的短期安全性和耐受性。 在第I阶段，确定vicriviroc联合优化背景治疗（包括利托那韦增强的蛋白酶抑制剂）的多剂量药代动力学，并确定在儿童和青少年中达到目标Cmin的vicriviroc剂量。 在第II阶段，评价优化剂量的vicriviroc联合优化背景治疗（包括利托那韦增强的蛋白酶抑制剂）在HIV感染、治疗经验丰富的儿童和青少年中的长期安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In Stage I, to evaluate the short term safety and tolerability of vicriviroc in combination with optimized background therapy which includes a ritonavir-boosted protease inhibitor regimen in HIV-infected, treatment experienced children and adolescents. In Stage I, to determine the multi-dose pharmacokinetics of vicriviroc in combination with optimized background therapy which includes a ritonavir-boosted protease inhibitor, and to determine the dose of vicriviroc that achieves a target Cmin in children and adolescents. In Stage II, to evaluate the long term safety and tolerability of the optimized dosage of vicriviroc in combination with optimized background therapy which includes a ritonavir-boosted protease inhibitor in HIV-infected, treatment experienced children and adolescents.